A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 [rimonabant] With or Without Hypocaloric Diet in Obese Patients.
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms REBA
- Sponsors Sanofi
- 12 May 2009 Actual patient number (156) added as reported by ClinicalTrials.gov.
- 12 May 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 05 Jul 2007 New trial record.